Consort Medical Takes Nearly 20 Percent Stake in Atlas Genetics | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Consort Medical, a UK-based manufacturer of drug delivery and medical device technologies, has acquired a roughly 20 percent stake in Atlas Genetics for £1.1 million ($1.8 million).

The firms also announced an alliance, under which Consort's Bespak division will design disposable test cards that will be part of Atlas' rapid, point-of-care molecular diagnostics system. Consort said that it also has received long-term manufacturing rights for the cards.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.